Articles tagged with: Integrase Inhibitors
Headline, News »
Updated results from a 96-week Phase 3 clinical trial continue to indicate that the investigational integrase inhibitor elvitegravir is as effective and safe as Isentress in previously treated people with HIV.
“These positive two-year data indicate that elvitegravir has the potential to be an important new once-daily treatment option for people living with HIV who have developed resistance to other therapies,” said Norbert Bischofberger, executive vice president of Research and Development and chief scientific officer of Gilead Sciences, which is developing elvitegravir, in a press release.
“In addition, we are…
Headline, News »
Interim results from an ongoing Phase 2 clinical trial show that the once-daily investigational integrase inhibitor dolutegravir may be as safe and effective as Sustiva in previously untreated HIV-positive adults.
“The most important message from the study is that dolutegravir is a safe and highly potent drug which can be given at low doses without a pharmacologic booster once daily,” said Dr. Jan van Lunzen, a professor at the University Medical Center Hamburg-Eppendorf, in Hamburg, Germany and lead author of the study.
“Thus it has the potential to be a…
Headline, News »
Interim results from a Phase 3 clinical trial show that the investigational integrase inhibitor elvitegravir, taken once daily, may be as effective and safe as twice-daily Isentress in treatment-experienced HIV-positive adults.
“[Patients] could use elvitegravir [once daily] instead of Isentress [twice daily] in combination with a boosted protease inhibitor with the same efficacy and safety,” said Dr. Jean-Michel Molina, a researcher at the Hôpital Saint Louis and University of Paris and lead author of the study.
The study authors noted that once daily dosing as opposed to twice daily dosing…
News »
ACLU Sues Alabama For Segregating HIV-Positive Prisoners – The American Civil Liberties Union (ACLU) has filed a lawsuit against the Alabama Department of Corrections for segregating HIV-positive prisoners from the rest of the inmate population. According to the suit, prisoners with HIV are housed separately, which reveals their HIV status and prevents them from participating in certain work release and other programs. The Department of Corrections states that HIV-positive prisoners have access to the same programs and that the segregation does not violate any of the prisoners’ rights; the Department has asked that the lawsuit be dismissed. For more information, please see the article on the CBS news site.
AIDS.gov Opens “Facing AIDS 2011” Campaign For World AIDS Day – To commemorate World AIDS Day on December 1, AIDS.gov is raising awareness through its “Facing AIDS 2011” campaign. Interested individuals are encouraged to download a “Facing AIDS” flier from the website and share why they are facing AIDS. Participants can take photos of themselves with their flier and then upload their images to the Facing AIDS website. All participants are encouraged to share their photos online with family and friends. Instructions on how to plan community events for the campaign are also available. For more information on how to participate, please see the AIDS.gov website.
Gilead Sciences Signs Agreement To Develop New Type Of Antiretroviral Drugs – Gilead Sciences has signed a licensing agreement with pharmaceutical company Boehringer Ingelheim to develop and market a new type of antiretroviral drug, initially pioneered by Boehringer Ingelheim. The new drugs are integrase inhibitors but work differently than Isentress (raltegravir) or the investigational drug elvitegravir. As a result, they are expected to be effective against HIV that is resistant to current integrase inhibitors. The agreement includes the investigational drug BI 224436, which has been tested in a Phase 1 clinical trial. For more information, please see the Gilead Sciences press release.
Theratechnologies Begins Development On New Lipodystrophy Drug – Theratechnologies announced last week that it has discovered a new potential drug in the same class as Egrifta (tesamorelin) and will begin pre-clinical testing of the new compound for treatment of lipodystrophy, a condition of abnormal fat distribution that is a side effect of certain anti-HIV medications. Theratechnologies stated that the new drug candidate appears to be as effective as Egrifta but may not need to be injected, as Egrifta is. Egrifta, which was approved in the U.S. in November of last year, was the first drug approved to treat lipodystrophy. For more information, please see the Theratechnologies press release.
Featured, Headline, News »
Interim results from an ongoing Phase 2b clinical trial indicate that once-daily dolutegravir, an investigational new integrase inhibitor, may be as safe and effective as Sustiva in people with HIV who have not previously been treated.
“Dolutegravir administered once daily…showed a rapid and sustained response at all doses explored through week 48,” said Dr. Jan van Lunzen, who presented the results yesterday at the 6th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention (IAS 2011).
“The drug in all dose groups was well tolerated, with fewer discontinuations occurring…